Binance founder Changpeng Zhao (CZ) donated $10 million in Binance Coin (BNB) to support Ethereum co-founder Vitalik Buterin’s open-source biotech initiatives, specifically through Buterin’s Kanro fund. The donation, made months prior to its announcement on July 1, 2025, aims to advance decentralized science (DeSci) by applying blockchain principles like transparency, open-source collaboration, and privacy to biotech research.
Buterin’s initiatives focus on areas such as biosecurity, pandemic preparedness, longevity research, and open-source vaccine development, using tools like zero-knowledge proofs to balance public health and privacy. CZ’s contribution, alongside investments from his family office YZi Labs, reflects a growing trend among crypto leaders to fund public-good projects, with CZ emphasizing mission-driven work to attract like-minded talent.
The crypto community praised the move, seeing it as a step toward revolutionizing biotech funding through decentralization. The donation bolsters DeSci’s mission to disrupt traditional biotech funding models by leveraging blockchain’s transparency, immutability, and decentralization. This could accelerate research in critical areas like biosecurity, pandemic preparedness, and longevity, making funding more accessible and less reliant on centralized institutions like governments or pharmaceutical giants.
Register for Tekedia Mini-MBA edition 18 (Sep 15 – Dec 6, 2025) today for early bird discounts. Do annual for access to Blucera.com.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment.
Tools like zero-knowledge proofs, emphasized in Buterin’s initiatives, could enable secure, privacy-preserving data sharing in biotech, potentially transforming how sensitive medical research is conducted and shared globally. CZ’s donation signals a shift among crypto leaders toward funding socially impactful projects. By channeling crypto wealth into biotech, it showcases blockchain’s potential beyond finance, potentially improving the industry’s public perception amid regulatory scrutiny. It sets a precedent for other crypto billionaires to fund open-source initiatives, fostering a culture of philanthropy within the space.
The collaboration between CZ (Binance) and Buterin (Ethereum) bridges two major blockchain ecosystems, potentially easing tensions between competing platforms. This could encourage more cross-chain partnerships, aligning the crypto industry toward shared goals like DeSci. It may inspire other exchanges or DeFi platforms to support similar initiatives, amplifying the impact of crypto-driven philanthropy.
Traditional biotech funding often faces high barriers, with venture capital and government grants favoring established players. DeSci’s decentralized model, backed by crypto donations, could democratize access to funding for smaller research teams or underrepresented regions, fostering innovation. The use of BNB for the donation highlights the growing utility of cryptocurrencies in real-world applications, potentially increasing adoption and legitimacy.
Success in Kanro’s focus areas—such as open-source vaccines or longevity research—could yield breakthroughs with global benefits, particularly in underserved areas. This aligns with CZ’s stated goal of attracting mission-driven talent to crypto and biotech. It could also spur regulatory discussions on how crypto-funded research fits into existing frameworks, potentially shaping policies around DeSci.
Many in the crypto space view this as a landmark move for DeSci and crypto’s societal impact. Enthusiasts on platforms like X celebrated the donation as a step toward proving blockchain’s utility beyond speculation, with some calling it a “game-changer” for biotech funding. Others question the motives, suspecting it’s a publicity move by CZ to bolster Binance’s image amid past regulatory issues. Some crypto purists argue that funds should prioritize blockchain development over external fields like biotech, seeing it as a distraction from crypto’s core mission.
Biotech researchers supportive of DeSci see this as a validation of blockchain’s potential to disrupt their field. The promise of transparent, decentralized funding is appealing, especially for those frustrated by bureaucratic grant systems. Traditional biotech stakeholders may view crypto-funded initiatives with skepticism, citing concerns about the volatility of cryptocurrencies like BNB, regulatory uncertainties, and the lack of established oversight in DeSci projects. Some may dismiss it as a speculative venture rather than serious science.
The donation underscores a broader ideological clash between centralized systems (traditional biotech funding, regulatory bodies) and decentralized models (DeSci, crypto-driven philanthropy). Centralized systems prioritize control and established protocols, while DeSci advocates for open access and community-driven innovation, creating tension over legitimacy and scalability. Regulatory bodies may push back against DeSci’s growth, fearing issues like money laundering or unverified research, while DeSci proponents argue that decentralization ensures greater transparency and accountability.
The donation highlights the growing wealth of crypto leaders like CZ and Buterin, raising questions about the concentration of power in the crypto space. While the donation is altruistic, some critics argue it reinforces a narrative of crypto elites wielding outsized influence, potentially alienating smaller retail investors or grassroots biotech researchers. Conversely, supporters see this as a positive use of crypto wealth, redistributing resources to underserved areas of science and challenging traditional gatekeepers.
Volatility in BNB’s value could complicate the donation’s real-world impact, as its $10 million valuation at the time of donation may fluctuate. This raises concerns about the reliability of crypto-based funding for long-term research. Integrating blockchain tools like zero-knowledge proofs into biotech requires technical expertise, which may create a learning curve for researchers unfamiliar with crypto systems, potentially slowing adoption.
CZ’s $10 million BNB donation to Buterin’s biotech initiative is a bold step toward merging crypto and biotech, with the potential to revolutionize funding and transparency in scientific research. It strengthens the case for DeSci and crypto’s broader societal role but also exposes divides between centralized and decentralized systems, crypto purists and pragmatists, and traditional biotech and DeSci advocates. The success of this initiative will depend on overcoming technical, regulatory, and cultural hurdles, but it could pave the way for a new era of decentralized, community-driven science.